A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype

[1]  Kaiyu Qian,et al.  Conditional reprogramming: Modeling urological cancer and translation to clinics , 2020, Clinical and translational medicine.

[2]  Jing Xie,et al.  CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells , 2020, Journal of Cancer.

[3]  Xinghuan Wang,et al.  Comprehensive genomic profiling of urothelial carcinoma cell lines reveals hidden research bias and caveats , 2020, Clinical and translational medicine.

[4]  John Garcia,et al.  Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing , 2018, The Prostate.

[5]  Xue Wu,et al.  EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  S. Boyault,et al.  Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men. , 2019, European urology.

[7]  J. Aerts,et al.  Novel EGFR V834L Germline Mutation Associated With Familial Lung Adenocarcinoma , 2018, JCO precision oncology.

[8]  A. Chinnaiyan,et al.  Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer , 2018, Cell.

[9]  Yi Mi Wu,et al.  The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.

[10]  R. Verhaak,et al.  The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations , 2017, bioRxiv.

[11]  K. Cooney,et al.  Germline genetic variants in men with prostate cancer and one or more additional cancers , 2017, Cancer.

[12]  K. Hemminki,et al.  Familial Associations Between Prostate Cancer and Other Cancers. , 2017, European urology.

[13]  S. Agarwal,et al.  Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens , 2017, Nature Protocols.

[14]  J. Beebe-Dimmer,et al.  Familial prostate cancer. , 2016, Seminars in oncology.

[15]  A. D'Amico,et al.  Screening for familial and hereditary prostate cancer , 2016, International journal of cancer.

[16]  I. Tannock,et al.  Prostate cancer , 2016, The Lancet.

[17]  T. Morii,et al.  V843I, a Lung Cancer Predisposing EGFR Mutation, Is Responsible for Resistance to EGFR Tyrosine Kinase Inhibitors , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  M. Ladanyi,et al.  Germline EGFR T790M mutation found in multiple members of a familial cohort. , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.